Bert Vogelstein, MD, of Johns Hopkins University discovered new genetic pathways and processes contributing to cancer. Using cutting edge technologies and approaches, he identified new genetic defects that alter cell signaling, promote cell growth, and compromise the integrity of DNA repair. The work from his laboratory has advanced our understanding of cancer pathogenesis and led to the development of new diagnostic tests and targeted therapies for cancer.
2019 Genetics Prize Recipient
Bert Vogelstein, MD, of the Kimmel Cancer at the Johns Hopkins University School of Medicine, has been at the forefront of cancer research for decades. His group has laid vital pieces of the framework for the field of cancer genetics starting in the 1980s with their discovery that colorectal tumors are clonal, that is, derived from a single cell. They subsequently found that genetic alterations in oncogenes and tumor suppressor genes drive colorectal tumorigenesis and that these alterations are often accumulated in a stereotyped, stepwise fashion. Together, these massive conceptual advances underlie our current understanding of how all common cancer types develop.
In the course of this work, Vogelstein’s group has identified mutations in many of the most important cancer driver genes. Among them are TP53, which is now known to be the most commonly mutated tumor suppressor gene in human cancers, and PIK3CA, the most commonly mutated oncogene in human cancers. Some of their discoveries, such as genetic alterations in PIK3CA and IDH1 and IDH2 have led to the successful development of drugs that target the mutated gene's protein products. Vogelstein's group co-discovered the genetic alterations responsible for mismatch repair defects in tumors. Two decades later, they discovered a treatment for these tumors, applicable to 4% of all advanced cancers. Thus, his findings have not only greatly increased our understanding of how cancer develops but also provided therapeutic targets and FDA-approved drugs that exploit these targets.
Along the way to these and other discoveries, Vogelstein’s team didn’t limit themselves to the techniques available at the time—they created their own, some of which have gone on to be used by innumerable researchers in labs studying a broad range of topics. For instance, his group’s paper about their method for radioactively labeling DNA has now garnered over 20,000 citations. As another example, he and his long-time colleague Kenneth W. Kinzler invented a technique called digital polymerase chain reaction (PCR) for finding rare mutations in DNA samples. Digital PCR turned out not only to be useful for this purpose, but also for quantifying the results of next-generation sequencing of DNA, one of the most important techniques in modern biological research.
In recent years, Vogelstein’s group has increasingly shifted their efforts toward developing methods for early detection of cancer such as those enabling the detection of rare mutations. Compared to developing new drugs for advanced cancers, Vogelstein believes too little research effort is now being directed toward creating and refining early detection methods given the number of lives it could save—so his plan is to continue to devote a substantial part of his lab's efforts towards early detection in the coming years.
The Gruber Foundation proudly presents the 2019 Genetics Prize to Bert Vogelstein for his discoveries of new genetic pathways and processes contributing to cancer. He showed that malignant transformation of colorectal cancers results from the stepwise acquisition of mutations in oncogenes and tumor suppressor genes, thus elucidating the somatic evolution of cancer. Using cutting edge technologies and approaches, he identified new genetic defects that alter cell signaling, promote cell growth, and compromise the integrity of DNA repair. His work has advanced our understanding of cancer pathogenesis and led to the development of new diagnostic tests and targeted therapies for cancer.